---
schema_version: "secwatch.filing_event.v1"
accession: "0000920148-25-000093"
form_type: "8-K"
ticker: "LH"
cik: "0000920148"
company_name: "LABCORP HOLDINGS INC."
filed_at: "2025-10-28T23:59:59+00:00"
generated_at: "2026-05-17T02:07:14.634521+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Labcorp Q3 adjusted EPS $4.18 vs $3.50; raises FY adjusted EPS midpoint to $16.15-$16.50

## Summary
- Revenue $3.56B (+8.6% YoY); diluted EPS $3.12 (vs $2.00); adjusted EPS $4.18 (vs $3.50).
- Full-year guidance: revenue growth 7.4%-8.0% (midpoint lowered 40 bps), adjusted EPS $16.15-$16.50 (midpoint +$0.05).
- Free cash flow 9M 2025 $715.7M; FY guidance raised to $1.17B-$1.29B.
- Acquired oncology assets from BioReference, signed deals with Empire City Labs, Laboratory Alliance, and Crouse Health.
- Quarterly dividend $0.72/share payable Dec 11, 2025; repurchased $25M stock in Q3.

## SEC filing metadata
- accession: 0000920148-25-000093
- form_type: 8-K
- ticker: LH
- cik: 0000920148
- company_name: LABCORP HOLDINGS INC.
- filed_at: 2025-10-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/920148/000092014825000093/0000920148-25-000093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/920148/000092014825000093/lh-20251028.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000920148-25-000093
- JSON: https://secwatch.observer/filing/0000920148-25-000093.json
- Plain text: https://secwatch.observer/filing/0000920148-25-000093.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.